1. Home
  2. DOMH vs VIRX Comparison

DOMH vs VIRX Comparison

Compare DOMH & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOMH
  • VIRX
  • Stock Information
  • Founded
  • DOMH 1967
  • VIRX 2007
  • Country
  • DOMH United States
  • VIRX United States
  • Employees
  • DOMH N/A
  • VIRX N/A
  • Industry
  • DOMH Biotechnology: Pharmaceutical Preparations
  • VIRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOMH Health Care
  • VIRX Health Care
  • Exchange
  • DOMH Nasdaq
  • VIRX Nasdaq
  • Market Cap
  • DOMH 8.8M
  • VIRX 6.8M
  • IPO Year
  • DOMH N/A
  • VIRX N/A
  • Fundamental
  • Price
  • DOMH $3.02
  • VIRX $0.08
  • Analyst Decision
  • DOMH
  • VIRX Buy
  • Analyst Count
  • DOMH 0
  • VIRX 4
  • Target Price
  • DOMH N/A
  • VIRX $5.00
  • AVG Volume (30 Days)
  • DOMH 421.3K
  • VIRX 2.1M
  • Earning Date
  • DOMH 03-31-2025
  • VIRX 03-06-2025
  • Dividend Yield
  • DOMH N/A
  • VIRX N/A
  • EPS Growth
  • DOMH N/A
  • VIRX N/A
  • EPS
  • DOMH N/A
  • VIRX N/A
  • Revenue
  • DOMH $12,589,000.00
  • VIRX N/A
  • Revenue This Year
  • DOMH N/A
  • VIRX N/A
  • Revenue Next Year
  • DOMH N/A
  • VIRX N/A
  • P/E Ratio
  • DOMH N/A
  • VIRX N/A
  • Revenue Growth
  • DOMH 1117.50
  • VIRX N/A
  • 52 Week Low
  • DOMH $0.83
  • VIRX $0.07
  • 52 Week High
  • DOMH $4.35
  • VIRX $1.31
  • Technical
  • Relative Strength Index (RSI)
  • DOMH 65.22
  • VIRX 20.79
  • Support Level
  • DOMH $2.86
  • VIRX $0.14
  • Resistance Level
  • DOMH $4.35
  • VIRX $0.19
  • Average True Range (ATR)
  • DOMH 0.52
  • VIRX 0.02
  • MACD
  • DOMH 0.14
  • VIRX -0.01
  • Stochastic Oscillator
  • DOMH 53.19
  • VIRX 0.00

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.

About VIRX Viracta Therapeutics Inc.

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Share on Social Networks: